-
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
•
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues skyrocketing 342% year-on-year (YOY) to RMB980 million (USD135 million). This remarkable growth was primarily driven by an option payment from Japanese partner Takeda and robust sales of olverembatinib, the novel BCR-ABL1 tyrosine kinase inhibitor (TKI),…
-
Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment
•
China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has awarded Breakthrough Therapy Designation (BTD) to its olverembatinib, a novel BCR-ABL1 tyrosine kinase inhibitor (TKI). The designation is for the drug’s use in combination with low-intensity chemotherapy as…
-
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
•
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public offering (IPO) of 7,325,000 American depositary shares (ADSs) in the United States at USD 17.25 per share, prior to underwriting discounts and commissions. The ADSs are scheduled to begin trading on the Nasdaq Global Market…
-
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
•
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company’s financial capacity to further its research and development efforts in innovative oncology treatments.…
-
Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor
•
Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575), has submitted its market application, which has been officially accepted by regulatory authorities. The formulation is being produced in collaboration with Xuantai Pharmaceutical. This innovative treatment targets patients suffering from refractory or relapsed chronic lymphocytic…
-
Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations
•
The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855) lisaftoclax (APG-2575) and AceLink Therapeutics(Suzhou)’s AL01211 are on track to receive priority review and breakthrough therapy designation (BTD) statuses respectively from the US Food and Drug Administration (FDA). Lisaftoclax, an oral BCL-2 inhibitor, is indicated…
-
Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
•
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple clinical studies for its olverembatinib (HQP1351) and three clinical studies for its lisaftoclax (APG-2575) at the 66th American Society of Hematology (ASH) annual meeting. These presentations highlight the company’s commitment to advancing treatments for various…
-
Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC
•
China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) to conduct two separate Phase III clinical studies assessing its investigational drug APG-2449. The trials will evaluate the FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI)…
-
Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of clinical study results for its drug olverembatinib (HQP1351) at the 2024 European Society of Medical Oncology (ESMO) Congress. The study focused on patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor (GIST), a rare and aggressive form…
-
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim results for the first half of the year, setting a new revenue record with a staggering 477% year-on-year (YOY) increase, reaching RMB 824 million (USD 115.4 million). The lion’s share of this revenue came from…
-
Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS
•
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a multi-center, randomized, double-blind Phase III study evaluating the efficacy of its novel drug, lisaftoclax (APG-2575), in combination with azacitidine (AZA) for the first-line treatment of newly diagnosed patients with higher-risk…
-
Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received marketing approval from the Macau Special Administrative Region (SAR) of China for its drug olverembatinib. This novel BCR-ABL1 tyrosine kinase inhibitor (TKI) is indicated for the treatment of adult patients with chronic-phase chronic myeloid…
-
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received a USD 100 million option rights payment from its Japanese partner Takeda (TYO: 4502), in accordance with an exclusive option agreement signed earlier last month. In June 2024, Takeda and Ascentage entered into an…
-
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
•
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking potential partnerships with Chinese biotech firms, according to CEO Christophe Weber in a recent Bloomberg interview. Weber highlighted that despite finalizing two recent agreements with Chinese companies, Takeda is still “very open” to further collaborations,…
-
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy. THDBH120, which is being developed to treat type 2 diabetes…
-
Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of multiple clinical trials for two of its pipeline candidates at the 29th European Hematology Association (EHA) Annual Meeting. The candidates are olverembatinib, a Category 1 drug and approved BCR-ABL inhibitor, and the investigational BCL-2 inhibitor…
-
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
•
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an option agreement with China-based Ascentage Pharma (HKG: 6855), securing exclusive development and commercialization rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in markets outside of China, Hong Kong, Macau, Taiwan, and Russia. The…
-
Ascentage Pharma Gets Green Light for Global Phase III Trial of Olverembatinib in SDH-Deficient GIST
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to initiate a global regulatory Phase III study for its Category 1 drug olverembatinib. The study aims to evaluate the efficacy of olverembatinib in…
-
Ascentage Pharma’s APG-2449 Shows Positive Results in ROS1 and ALK Positive NSCLC at ASCO 2024
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in Suzhou, has announced a wall poster presentation showcasing the latest data for its FAK/ALK/ROS1 inhibitor APG-2449 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The study determined the recommended Phase II dosage (RP2D) of APG-2449 to be 1200…
-
Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024
•
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4 in Chicago, will feature updates from Chinese pharmaceutical companies Ascentage Pharma (HKG: 6855), Lepu Biotechnology Co., Ltd (HKG: 2157), Transcenta Holding Ltd, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) on their…
